Tenofovir-associated bone density loss

References

• PozniakATenofovir: what have over 1 million years of patient experience taught us?Int J Clin Pract20086281285129318705824
   PubMed Web of Science ®Google Scholar
• StephanCExperience with tenofovir disoproxil fumarate for antiretroviral therapyExpert Opin Pharmacother2008971197120918422476
   PubMed Web of Science ®Google Scholar
• MargotNAIsaacsonEMcGowanIChengAKSchooleyRTMillerMDGenotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DFAIDS20021691227123512045487
   PubMed Web of Science ®Google Scholar
• SchooleyRTRuanePMyersRATenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind studyAIDS20021691257126312045491
   PubMed Web of Science ®Google Scholar
• SquiresKPozniakALPieroneGJrTenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trialAnn Intern Med20031395 Pt 131332012965939
   PubMed Web of Science ®Google Scholar
• KarsdalMAMartinTJBollerslevJChristiansenCHenriksenKAre nonresorbing osteoclasts sources of bone anabolic activity?J Bone Miner Res200722448749417227224
   PubMed Web of Science ®Google Scholar
• KarsdalMAHenriksenKSorensenMGAcidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorptionAm J Pathol2005166246747615681830
   PubMed Web of Science ®Google Scholar
• MartinTJSimsNAOsteoclast-derived activity in the coupling of bone formation to resorptionTrends Mol Med2005112768115694870
   PubMed Web of Science ®Google Scholar
• BollerslevJMarksSCJrPockwinseSUltrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosisBone19931468658698155410
   PubMed Web of Science ®Google Scholar
• BollerslevJSteinicheTMelsenFMosekildeLStructural and histomorphometric studies of iliac crest trabecular and cortical bone in autosomal dominant osteopetrosis: a study of two radiological typesBone198910119242660883
   PubMed Web of Science ®Google Scholar
• AlataloSLIvaskaKKWaguespackSGEconsMJVaananenHKHalleenJMOsteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis)Clin Chem200450588389015016726
   PubMed Web of Science ®Google Scholar
• CecchiniMGHofstetterWHalasyJWetterwaldAFelixRRole of CSF-1 in bone and bone marrow developmentMol Reprod Dev19974617583 discussion 83–74.8981367
   PubMed Web of Science ®Google Scholar
• WadaTNakashimaTHiroshiNPenningerJMRANKL-RANK signaling in osteoclastogenesis and bone diseaseTrends Mol Med2006121172516356770
   PubMed Web of Science ®Google Scholar
• FelixRCecchiniMGHofstetterWElfordPRStutzerAFleischHImpairment of macrophage colony-stimulating factor production and lack of resident bone marrow macrophages in the osteopetrotic op/op mouseJ Bone Miner Res1990577817892204254
   PubMed Web of Science ®Google Scholar
• Wiktor-JedrzejczakWBartocciAFerranteAWJrTotal absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouseProc Natl Acad Sci U S A19908712482848322191302
   PubMed Web of Science ®Google Scholar
• YoshidaHHayashiSKunisadaTThe murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor geneNature199034562744424442188141
   PubMed Web of Science ®Google Scholar
• BonnelyeEMerdadLKungVAubinJEThe orphan nuclear estrogen receptor-related receptor alpha (ERRalpha) is expressed throughout osteoblast differentiation and regulates bone formation in vitroJ Cell Biol2001153597198411381083
   PubMed Web of Science ®Google Scholar
• LiuRHWerthVPWhat is new in the treatment of steroid-induced osteoporosis?Semin Cutan Med Surg200726420320918395668
   PubMed Web of Science ®Google Scholar
• ShakerJLLukertBPOsteoporosis associated with excess glucocorticoidsEndocrinol Metab Clin North Am2005342341356viiiix15850846
   PubMed Web of Science ®Google Scholar
• CaplanLSaagKGGlucocorticoids and the risk of osteoporosisExpert Opin Drug Saf200981334719236216
   PubMed Web of Science ®Google Scholar
• EbelingPROsteoporosis in men. New insights into aetiology, pathogenesis, prevention and managementDrugs Aging19981364214349883398
   PubMed Web of Science ®Google Scholar
• McIlwainHHGlucocorticoid-induced osteoporosis: pathogenesis, diagnosis, and managementPrev Med200336224324912591000
   PubMed Web of Science ®Google Scholar
• PietschmannPRaunerMSiposWKerschan-SchindlKOsteoporosis: an age-related and gender-specific disease – a mini-reviewGerontology200855131218948685
   PubMed Web of Science ®Google Scholar
• FrameBParfittAMOsteomalacia: current conceptsAnn Intern Med1978896966982363010
   PubMed Web of Science ®Google Scholar
• MisraMPacaudDPetrykACollett-SolbergPFKappyMVitamin D deficiency in children and its management: review of current knowledge and recommendationsPediatrics2008122239841718676559
   PubMed Web of Science ®Google Scholar
• UkincKSevere osteomalacia presenting with multiple vertebral fractures: a case report and review of the literatureEndocrine2009361303619543841
   PubMed Web of Science ®Google Scholar
• Segovia-SilvestreTNeutzsky-WulffAVSorensenMGAdvances in osteoclast biology resulting from the study of osteopetrotic mutationsHum Genet2009124656157718987890
   PubMed Web of Science ®Google Scholar
• SlyWSHewett-EmmettDWhyteMPYuYSTashianRECarbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcificationProc Natl Acad Sci U S A1983809275227566405388
   PubMed Web of Science ®Google Scholar
• BoydenLMMaoJBelskyJHigh bone density due to a mutation in LDL-receptor-related protein 5N Engl J Med2002346201513152112015390
   PubMed Web of Science ®Google Scholar
• Van WesenbeeckLCleirenEGramJSix novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone densityAm J Hum Genet200372376377112579474
   PubMed Web of Science ®Google Scholar
• ArpadiSMHorlickMThorntonJCuffPAWangJKotlerDPBone mineral content is lower in prepubertal HIV-infected childrenJ Acquir Immune Defic Syndr200229545045411981360
   PubMed Web of Science ®Google Scholar
• TebasPPowderlyWGClaxtonSAccelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapyAIDS2000144F636710770534
   PubMed Web of Science ®Google Scholar
• ViganoAMoraSAdverse effects of antiretroviral therapy: focus on bone densityExpert Opin Drug Saf20043319920815155148
   PubMedGoogle Scholar
• MadedduGSpanuASolinasPBone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapyQ J Nucl Med Mol Imaging2004481394815195003
   PubMed Web of Science ®Google Scholar
• CastilloABTarantalAFWatnikMRMartinRBTenofovir treatment at 30 mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta)J Orthop Res20022061185118912472227
   PubMed Web of Science ®Google Scholar
• TarantalAFMarthasMLShawJPCundyKBischofbergerNAdministration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studiesJ Acquir Immune Defic Syndr Hum Retrovirol199920432333310096575
   PubMedGoogle Scholar
• Van RompayKKBrignoloLLMeyerDJBiological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy) propyl]adenine (tenofovir) to newborn and infant rhesus macaquesAntimicrob Agents Chemother20044851469148715105094
   PubMed Web of Science ®Google Scholar
• GallantJEStaszewskiSPozniakALEfficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trialJAMA2004292219120115249568
   PubMed Web of Science ®Google Scholar
• HazraRGafniRIMaldarelliFTenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infectionPediatrics20051166e846e85416291735
   PubMed Web of Science ®Google Scholar
• GafniRIHazraRReynoldsJCTenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected childrenPediatrics20061183e711e71816923923
   PubMed Web of Science ®Google Scholar
• PurdyJBGafniRIReynoldsJCZeichnerSHazraRDecreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virusJ Pediatr2008152458258418346519
   PubMed Web of Science ®Google Scholar
• FuxCARauchASimcockMTenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort StudyAntivir Ther20081381077108219195333
   PubMed Web of Science ®Google Scholar
• GiacometVMoraSMartelliLMerloMSciannambloMViganoAA 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected childrenJ Acquir Immune Defic Syndr200540444845016280700
   PubMed Web of Science ®Google Scholar
• CoteHCMechanisms of antiretroviral therapy-induced mitochondrial dysfunctionCurr Opin HIV AIDS20072425326019372896
   PubMed Web of Science ®Google Scholar
• LewisWCopelandWCDayBJMitochondrial dna depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitorsLab Invest200181677779011406640
   PubMed Web of Science ®Google Scholar
• LewisWDayBJCopelandWCMitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspectiveNat Rev Drug Discov200321081282214526384
   PubMed Web of Science ®Google Scholar
• LewisWKohlerJJHosseiniSHAntiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesisAIDS200620567568416514297
   PubMed Web of Science ®Google Scholar
• KohlerJJLewisWA brief overview of mechanisms of mitochondrial toxicity from NRTIsEnviron Mol Mutagen20074834166172
   Web of Science ®Google Scholar
• LeeHHanesJJohnsonKAToxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymeraseBiochemistry20034250147111471914674745
   PubMed Web of Science ®Google Scholar
• DesaiVGLeeTDelongchampRRNucleoside reverse transcriptase inhibitors (NRTIs)-induced expression profile of mitochondria-related genes in the mouse liverMitochondrion20088218119518313992
   PubMed Web of Science ®Google Scholar
• DesaiVGLeeTMolandCLEffect of short-term exposure to zidovudine (AZT) on the expression of mitochondria-related genes in skeletal muscle of neonatal miceMitochondrion20099191618824140
   PubMed Web of Science ®Google Scholar
• MallonPWUnemoriPSedwellRIn vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNAJ Infect Dis2005191101686169615838796
   PubMed Web of Science ®Google Scholar
• VidalFDomingoJCGuallarJIn vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cellsAntimicrob Agents Chemother200650113824383216940060
   PubMed Web of Science ®Google Scholar
• CihlarTBirkusGGreenwaltDEHitchcockMJTenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitorsAntiviral Res2002541374511888656
   PubMed Web of Science ®Google Scholar
• BirkusGHitchcockMJCihlarTAssessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitorsAntimicrob Agents Chemother200246371672311850253
   PubMed Web of Science ®Google Scholar
• BieseckerGKarimiSDesjardinsJEvaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucksAntiviral Res200358321722512767469
   PubMed Web of Science ®Google Scholar
• GerschensonMKimCBerzinsBMitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimenJ Antimicrob Chemother20096361244125019321503
   PubMed Web of Science ®Google Scholar
• RiberaEParadineiroJCCurranAImprovements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study)HIV Clin Trials20089640741719203906
   PubMed Web of Science ®Google Scholar
• MiroOGarrabouGLopezSShort communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavirAntivir Ther200611562563016964831
   PubMed Web of Science ®Google Scholar
• LebrechtDVenhoffACKirschnerJWiechTVenhoffNWalkerUAMitochondrial tubulopathy in tenofovir disoproxil fumarate-treated ratsJ Acquir Immune Defic Syndr200951325826319582894
   PubMed Web of Science ®Google Scholar
• KohlerJJHosseiniSHHoying-BrandtATenofovir renal toxicity targets mitochondria of renal proximal tubulesLab Invest200989551351919274046
   PubMed Web of Science ®Google Scholar
• KwakHBKimJYKimKJRisedronate directly inhibits osteoclast differentiation and inflammatory bone lossBiol Pharm Bull20093271193119819571384
   PubMed Web of Science ®Google Scholar
• MoreauMFGuilletCMassinPComparative effects of five bisphosphonates on apoptosis of macrophage cells in vitroBiochem Pharmacol200773571872317157266
   PubMed Web of Science ®Google Scholar
• EarleKESeneviratneTShakerJShobackDFanconi’s syndrome in HIV+ adults: report of three cases and literature reviewJ Bone Miner Res200419571472115068493
   PubMed Web of Science ®Google Scholar
• ParsonageMJWilkinsEGSnowdenNIssaBGSavageMWThe development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapyHIV Med20056534134616156882
   PubMed Web of Science ®Google Scholar
• WilliamsJChadwickDRTenofovir-induced renal tubular dysfunction presenting with hypocalcaemiaJ Infect2006524e107e10816125779
   PubMedGoogle Scholar
• NelsonMRKatlamaCMontanerJSThe safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 yearsAIDS200721101273128117545703
   PubMed Web of Science ®Google Scholar
• LabargaPBarreiroPMartin-CarboneroLKidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovirAIDS200923668969619262355
   PubMed Web of Science ®Google Scholar
• WoodwardCLHallAMWilliamsIGTenofovir-associated renal and bone toxicityHIV Med200910848248719459988
   PubMed Web of Science ®Google Scholar
• PerrotSAslangulESzwebelTCaillat-VigneronNLe JeunneCBone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patientJ Clin Rheumatol2009152727419265350
   PubMed Web of Science ®Google Scholar
• CalmyAFuxCANorrisRLow bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional studyJ Infect Dis2009200111746175419874178
   PubMed Web of Science ®Google Scholar
• Di BiagioARossoRMontefortePRussoRRovettaGViscoliCWhole body bone scintigraphy in tenofovir-related osteomalacia: a case reportJ Med Case Reports20093813619830218
   PubMedGoogle Scholar